Subsidiaries of Astellas and Novartis co-led a series B round that took Harvard's cancer treatment developer's overall funding to $60m.
TScan Therapeutics, a US-based oncology therapy spinout of Harvard University, has closed a $35m series B round that included vehicles for pharmaceutical firms Astellas and Novartis.
Novartis Institutes for BioMedical Research and Astellas Venture Management co-led the round with venture capital fund Pitango Venture Capital, while Novartis also invested through its Novartis Venture Fund.
Internet and technology group Alphabet took part in the round through its GV unit. It included 6 Dimensions Capital, the investment firm co-founded by…
